Study Details

Back to Search Results

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02639182

Astellas Study ID

The unique identification code given by the study sponsor.

AGS-16C3F-15-3

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Kidney Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

AGS-16C3F

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

May 2016 - Oct 2020

Masking

None (Open Label)

Enrollment number

133

A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US01025

Dallas, United States, 75246

Site US01011

Charleston, United States, 29425

Site US01010

Atlanta, United States, 30322

Site CA02008

London, Canada, N6A 5W9

Site US01012

Omaha, United States, 68130

Site US01019

Palo Alto, United States, 94305

Site US01003

Houston, United States, 77030

Site CA02001

Vancouver, Canada, V5Z 4E6

Site US01002

Boston, United States, 02215

Site US01006

Buffalo, United States, 14263

Site US01001

Seattle, United States, 98109

Site US01013

Detroit, United States, 48202

Site US01021

Pittsburgh, United States, 15232

Site US01005

Las Vegas, United States, 89169

Site US01016

Encinitas, United States, 92011

Site US01014

Temple, United States, 76508

Site US01023

Baltimore, United States, 21201

Site US01015

Oklahoma City, United States, 73104

Site US01009

Milwaukee, United States, 53226

Site US01026

Tucson, United States, 85719

Site CA02005

Kelowna, Canada, V1Y 5L3

Site US01004

Ann Arbor, United States, 48109

Site CA02004

Edmonton, Canada, T6G 1Z2

Site CA02002

Hamilton, Canada, L8V 5C2

Site CA02006

Calgary, Canada, T2N 4N2

Site US01008

La Jolla, United States, 92093

Site US01022

Durham, United States, 27710

Site US01017

Portland, United States, 97213

Site US01018

Minneapolis, United States, 55455

Site US01007

Los Angeles, United States, 90033

Site US01020

Los Angeles, United States, 90095

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo